New Mode of Action Provides New Treatment Options for IBD

Although many treatments are available, there are still a limited number of courses of action, says Arnaud Bourreille, Associate Professor of Gastroenterology at the Institut des Maladies de l’Appareil Digestif in France. In this MEDtalk, he presents the latest data for the IL-7 antagonist lusvertikimab, which has shown improvements in clinical, histological, and endoscopic endpoints in patients with ulcerative colitis.